Omadacycline, a novel aminomethylcycline tetracycline, was developed to overcome major resistance mechanisms to older tetracyclines. It overcomes resistance by:

• A Its bulky C7-aminomethyl and C9-trifluoromethyl substitutions sterically prevent binding by Tet efflux pumps (TetA-E) and Tet ribosomal protection proteins (TetM, TetO), while retaining 30S ribosomal target binding ✓
• B Omadacycline binds to the 50S ribosomal subunit at the peptidyl transferase centre rather than the 30S subunit
• C Omadacycline is a prodrug activated by bacterial enzymatic reduction that inactivates ribosomal protection proteins
• D Omadacycline co-inhibits efflux pump ATPase while binding the ribosome, providing dual-mechanism resistance coverage

Explanation

Tetracycline resistance is mediated primarily by: (1) TetA-E efflux pumps (expel tetracycline from the cell) and (2) TetM/TetO ribosomal protection proteins (GTPases that chase tetracycline off the ribosome). Omadacycline's C7-aminomethyl substitution (derived from minocycline's aminomethyl group development, like tigecycline's glycylcycline modification) creates steric bulk that prevents the efflux protein binding site and occludes the groove on TetM that normally contacts tetracycline. This dual structural evasion while maintaining 30S ribosomal binding affinity confers activity against tetracycline-resistant Gram-positive and atypical pathogens. Omadacycline binds 30S, not 50S.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.